NCT01092741View on ClinicalTrials.gov

Late Chronic Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

December 31, 2006

Study Completion Date

September 30, 2013

Conditions
Leukemia
Interventions
DRUG

Gleevec

400 mg P.O. twice daily (800 mg total daily dose)

Trial Locations (1)

77030

The University Of MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01092741 - Late Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter